KRAS and non-small cell lung carcinoma: The subgroup analysis of CheckMate 057 study and OAK study indicated that during the second-line treatment for KRAS mutant NSCLC patients, immune checkpoint inhibitors (ICIs) monotherapy had a higher OS benefit than docetaxel monotherapy [34, 35].